Drug Type Small molecule drug |
Synonyms Albaconazole (USAN/INN), UR-9825, W 0027 + [1] |
Target |
Mechanism fungal CYP51A1 inhibitors(Fungal CYP51A1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H16ClF2N5O2 |
InChIKeyUHIXWHUVLCAJQL-MPBGBICISA-N |
CAS Registry187949-02-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09702 | Albaconazole | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Onychomycosis | Phase 2 | US | 16 Jul 2008 | |
Onychomycosis | Phase 2 | CA | 16 Jul 2008 | |
Onychomycosis | Phase 2 | IS | 16 Jul 2008 | |
Candidiasis, Vulvovaginal | Phase 2 | - | 01 Jun 2004 | |
Mycoses | Phase 2 | - | - | |
Mycoses | Phase 2 | - | - | |
Tinea Pedis | Phase 1 | US | 01 Jul 2007 | |
Tinea Pedis | Phase 1 | AU | 01 Jul 2007 | |
Chagas Disease | Preclinical | ES | - | - |
Phase 2 | 582 | (Albaconazole 400 mg (36 Weeks) Oral Weekly) | fxtqpiabku(vgzqotankb) = xmaxciagtp uofvmymasa (wrfzrdfqso, opwfqhpsfm - yntvkfsjkj) View more | - | 07 Feb 2018 | ||
(Albaconazole 400 mg (24 Weeks) Oral Weekly) | fxtqpiabku(vgzqotankb) = cyadhseeqr uofvmymasa (wrfzrdfqso, osttokuipb - nxpalorxov) View more |